Chronic pulmonary hypertension (CPH) encompasses a heterogeneous group of disorders with the common feature of elevated pulmonary vascular resistance, accounting for approximately 42 million cases ...
Mainstay Medical Published Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study On November 22, 2022, Mainstay Medical, a medical devices company, announced that the data from the ReActiv8®-C study, a single-centre, real-world study with a one-year clinical follow-up of selected patients, is publ...
Find More
RNA interference (RNAi) is a fundamental gene-silencing pathway in eukaryotic cells that involves an enzyme called dicer cleaving long pieces of double-stranded RNA into shorter fragments called siRNAs that can cleave complementary mRNA sequences with the help of the RISC complex and argonaute. RNA interference ...
Find More
Gene therapy is an experimental technique that introduces functional genes into a patient’s body to counteract or replace defective ones, thereby curing disease without using pharmaceuticals, radiotherapy, or surgery. Genetic defects that are difficult to treat with drugs or antibodies can be treated with therapy w...
Find More
Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in the US On November 15, 2022, Medtronic plc, a global leader in healthcare technology, announced the US launch of the Medtronic Extended infusion set, the first and only infusion set labeled for up to ...
Find More
QuantuMDx and Menarini Announced an Agreement for the Distribution of the Q-POCTM Platform On November 2, 2022, QuantuMDx Group Limited, a UK-based developer of transformational Point-of-Need molecular diagnostics, and A.Menarini Diagnostics S.r.I. (Menarini), announced an exclusive distribution agreement for Qu...
Find More
AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F18⁸⁵ PE System in Treatment of Pulmonary Embolism On October 31, 2022, AngioDynamics, a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer...
Find More
FDA Accepts Bristol Myers Squibb’s Supplemental New Drug Application for CAMZYOS Bristol Myers Squibb declared that the U.S. FDA had accepted its supplemental new drug application for CAMZYOS for an expanded indication to reduce the need for septal reduction therapy. CAMYZOS is currently FDA-approved for treatin...
Find More
HELIOSTAR™ Radiofrequency Balloon Ablation Catheter Launched by Biosense Webster in Europe On October 12, 2022, Biosense Webster, a part of Johnson & Johnson Medical technology, announced the launch of HELIOSTAR™ Balloon Ablation Catheter, the first radiofrequency balloon ablation catheter in E...
Find More
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) affects LDL receptor degradation and decreases the clearance of circulating LDL particles, which is crucial in cholesterol metabolism. PCSK9 is predominantly generated by hepatocytes, with additional sources including the intestines and kidneys. PCSK9 reduces LD...
Find More
Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....
Find More
Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....
Find More
Gene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Healt.....
Find MoreHear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.
